Imagine a scenario where a top drug regulator is accused of the very bias they once criticized in others. This is the paradoxical situation unfolding at the FDA, where Tracy Beth Høeg, set to lead the Center for Drug Evaluation and Research (CDER), faces internal concerns about her ability to remain impartial. But here’s where it gets controversial: Høeg, once a vocal critic of decision-making based on belief rather than science, now stands accused by FDA staff of potentially doing just that in her role as a scientific adviser.
Back in 2008, Høeg, then a resident physician and ultramarathon runner, penned a blog post (https://sealegsgirl.blogspot.com/2008/09/closer-look-at-palin.html) expressing dismay at Sarah Palin’s denial of climate change. She wrote, “To stare such abundant scientific evidence in the face and make the blanket statement that you don’t believe it… What will the future of the planet be in the hands of someone who bases their decisions on belief rather than scientific evidence?” Fast forward seventeen years, and Høeg’s own decisions are under scrutiny as she steps into one of the most critical roles in U.S. drug regulation—a position that demands dispassionate, evidence-based judgment.
As acting director of the CDER starting Monday, Høeg will oversee the evaluation of complex scientific data on the benefits and risks of medical treatments. Her supporters, including her bosses and former colleagues, insist she’s up to the task. Yet, her nine-month tenure as scientific adviser to FDA Commissioner Marty Makary has raised eyebrows. Critics within the FDA argue her track record suggests a potential for bias, a claim that echoes the very concerns she once voiced about others. And this is the part most people miss: the irony of Høeg’s situation isn’t just about her past statements—it’s about the broader implications for trust in regulatory science.
Is it possible for someone with a history of outspoken views to set aside personal beliefs and uphold impartiality in such a high-stakes role? Or does past advocacy inevitably cloud present judgment? These questions aren’t just about Høeg—they’re about the integrity of the systems we rely on to safeguard public health. As Høeg takes the helm at CDER, the FDA staff’s concerns highlight a deeper debate: Can regulators truly separate their personal convictions from their professional duties? What do you think? Share your thoughts in the comments—this is a conversation that demands diverse perspectives.
